Pharmaceutical firm Pfizer announced in a recent regulatory filing that it has received requests from the Department of Justice and the Securities and Exchange Commission regarding the company’s operations in China.
In a third-quarter report filed Nov. 5, Pfizer said it “received an informal request” from the Department of Justice’s Foreign Corrupt Practices Act (FCPA) Unit “seeking documents relating to our operations in China” in June 2020. The firm said it received a similar request from the SEC’s FCPA Unit in August, and that it is “producing records pursuant to these requests.”
Pfizer said it is also producing records in response to other informal requests from these agencies’ FCPA Units, which it received in June 2019 (DOJ) and September 2019 (SEC) relating to operations in Russia.
Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal, enforcement, technology, and more.
No comments yet